We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Synthetic Fatty Acid Derivatives Display Anti-Cancer Potential

By LabMedica International staff writers
Posted on 26 Jul 2018
Print article
Image: A ball-and-stick model of the docosahexaenoic acid (DHA) molecule. DHA is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina (Photo courtesy of Wikimedia Commons).
Image: A ball-and-stick model of the docosahexaenoic acid (DHA) molecule. DHA is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina (Photo courtesy of Wikimedia Commons).
Metabolites produced during digestion of omega-3 fatty acids have been found to have anti-cancer properties, and their synthetic derivatives have the potential to be developed into potent chemotherapeutic drugs.

Dietary omega-3 fatty acids, such as docosahexaenoic acid (DHA), have been shown to suppress tumor growth through their conversion to epoxide metabolites. Alternatively, DHA is converted enzymatically into docosahexaenoylethanolamide (DHEA), an endocannabinoid with anti-proliferative activity.

Investigators at the University of Illinois (Champaign-Urbana, USA) had previously described a novel class of anti-inflammatory DHEA-epoxide derivative called epoxydocospentaenoic-ethanolamide (EDP-EA) that contained both ethanolamide and epoxide moieties. To expand those findings they examined the anti-tumorigenic properties of EDP-EAs in an osteosarcoma (OS) mouse model.

The investigators showed an approximately 80% increase in EDP-EAs in metastatic versus normal lungs of mice. In addition they found significant differences in the apoptotic and anti-migratory potencies of different EDP-EA structural isomers, which were partially mediated through the cannabinoid receptor 1 (CB1). The cannabinoid receptor is represented in relatively high density on the surface of cancer cells.

The investigators then synthesized derivatives of the most pro-apoptotic isomer. These derivatives were found to display reduced hydrolytic susceptibility to fatty acid amide hydrolase (FAAH) and increased CB1-selective binding.

"We have a built-in endocannabinoid system which is anti-inflammatory and pain-reducing. Now we see it is also anti-cancer, stopping the cells from proliferating or migrating," said senior author Dr. Aditi Das, professor of comparative biosciences at the University of Illinois. "These molecules could address multiple problems: cancer, inflammation, and pain."

"The dramatic increase indicated that these molecules were doing something to the cancer - but we did not know if it was harmful or good," said Dr. Das. "We asked, are they trying to stop the cancer, or facilitating it? So we studied the individual properties and saw that they are working against the cancer in several ways. Dietary consumption of omega-3 fatty acids can lead to the formation of these substances in the body and may have some beneficial effects. However, if you have cancer, you want something concentrated and fast acting. That is where the endocannabinoid epoxide derivatives come into play - you could make a concentrated dose of the exact compound that is most effective against the cancer. You could also mix this with other drugs such as chemotherapies."

Related Links:
University of Illinois

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.